Moderna’s mNexspike Approval, Breast Cancer Vaccine Progress, Malaria Trials in Kids & More 🌍💉🧠
In this week’s edition of Vaccine Research Updates, we spotlight the most critical advancements shaping the next era of immunization and disease prevention. From high-impact FDA approvals to breakthroughs in cancer, malaria, and pediatric vaccines—here’s what’s transforming global public health:
💉 Moderna’s next-gen COVID-19 vaccine, mNexspike, receives FDA approval for adults aged 65+ and high-risk individuals aged 12–64—offering higher antibody levels with a smaller dose.
🌿 Curevo initiates a Phase 2 shingles vaccine trial comparing amezosvatein to Shingrix in adults 50+—targeting safer, more accessible immunization.
🧬 Anixa completes a Phase 1 breast cancer vaccine trial—over 70 percent of participants show immune response, with Phase 2 trials planned alongside Cleveland Clinic.
🧠 Tedopi® by OSE Immunotherapeutics delivers 65 percent 1-year survival in pancreatic cancer—plus two complete responses and strong safety data.
🦟 Sanaria’s PfSPZ-LARC2 malaria vaccine expands to children aged 6–19 in Burkina Faso—aiming to reshape malaria prevention in Sub-Saharan Africa.
🧑⚕️ Canid secures $10M to scale its AI-powered pediatric vaccine management platform—reducing administrative burdens across 12 U.S. states.
📢 Stay Ahead in Vaccine Research!
✅ Like, share, and subscribe for weekly updates on vaccine research
#VaccineResearch #COVID19Vaccines #BreastCancerVaccine #ShinglesVaccine #MalariaVaccine #Tedopi #LucidQuest #LQVentures #PublicHealth #ClinicalTrials #BiotechNews #HealthcareInnovation #mRNAVaccines #AIinHealthcare #PediatricVaccines #GlobalHealth #InfectiousDiseases #Anixa #OSEImmunotherapeutics #Sanaria #CanidHealth #FDAApproval #CancerImmunotherapy